Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus.

Influenza A virus is highly variable and a major viral respiratory pathogen that can cause severe illness in humans. Therefore it is important to induce a sufficient immune response specific to current strains and to heterosubtypic viruses with vaccines. In this study, we developed a dual-promoter-based bivalent DNA vaccine that encodes both hemagglutinin (HA) and nucleoprotein (NP) proteins from a highly pathogenic A/Chicken/Henan/12/2004 (H5N1) virus. Our results show that the expression levels of HA and NP genes from the dual-promoter plasmid are similar to those seen when they are expressed individually in independent plasmids. When the bivalent DNA vaccine was inoculated via intramuscular injection and in vivo electroporation, high levels of both humoral and cellular immune responses were elicited against homologous H5N1 virus and heterosubtypic H9N2 virus. Furthermore, no obvious antigenic competition was observed between HA and NP proteins in the dual-promoter-based bivalent vaccine compared to monovalent vaccines. Our data suggest that a combination of influenza surface and internal viral genes in a dual-promoter-expressing plasmid may provide a new approach for developing a DNA vaccine that may protect not only specifically against a currently circulating strain, but also may cross-protect broadly against new heterosubtypic viruses.

[1]  Boping Zhou,et al.  Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase , 2009, Vaccine.

[2]  Ron A M Fouchier,et al.  Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans , 2009, Science.

[3]  E. Lyons,et al.  Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings , 2009, Science.

[4]  H. Ertl,et al.  Pandemic Influenza Vaccines , 2009, Current topics in microbiology and immunology.

[5]  Jianjun Chen,et al.  A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice , 2009, BMC infectious diseases.

[6]  Zhiwei Chen,et al.  Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody , 2008, Virology.

[7]  T. Randall,et al.  A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus1 , 2008, The Journal of Immunology.

[8]  D. Ho,et al.  A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses , 2008, Proceedings of the National Academy of Sciences.

[9]  Chih-Jen Wei,et al.  Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity , 2007, Science.

[10]  M. Peiris,et al.  Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  K. Mozdzanowska,et al.  Prospects for Universal Influenza Virus Vaccine , 2006, Emerging infectious diseases.

[12]  S. Riedel.  Crossing the Species Barrier: The Threat of an Avian Influenza Pandemic , 2006, Proceedings.

[13]  Samson S. Y. Wong,et al.  Avian Influenza Virus Infections in Humans , 2006, Chest.

[14]  Yi Guan,et al.  Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003 , 2005, Journal of Clinical Microbiology.

[15]  Jianjun Chen,et al.  Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. , 2005, Vaccine.

[16]  Ze Chen,et al.  Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice , 2005, Biochemical and Biophysical Research Communications.

[17]  J. Wood,et al.  From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza , 2004, Nature Reviews Microbiology.

[18]  D. Wells,et al.  Gene Therapy Progress and Prospects: Electroporation and other physical methods , 2004, Gene Therapy.

[19]  T. Tjelle,et al.  In vivo electroporation improves immune responses to DNA vaccination in sheep. , 2004, Vaccine.

[20]  N. Cox,et al.  Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. , 2003, Virology.

[21]  L. Babiuk,et al.  Electroporation improves the efficacy of DNA vaccines in large animals. , 2002, Vaccine.

[22]  T. Tjelle,et al.  Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. , 2002, Vaccine.

[23]  K. Subbarao,et al.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. , 2002, Emerging infectious diseases.

[24]  J. Ulmer.  Influenza DNA vaccines. , 2002, Vaccine.

[25]  Scott N. Mueller,et al.  Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus 11 , 2002, The Journal of Immunology.

[26]  K Cameron,et al.  Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Kurata,et al.  Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. , 2000, Vaccine.

[28]  David E. Swayne,et al.  Continued Circulation in China of Highly Pathogenic Avian Influenza Viruses Encoding the Hemagglutinin Gene Associated with the 1997 H5N1 Outbreak in Poultry and Humans , 2000, Journal of Virology.

[29]  J. Ulmer,et al.  Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo , 2000, The Journal of Immunology.

[30]  R. Webster,et al.  DNA Vaccine Encoding Hemagglutinin Provides Protective Immunity against H5N1 Influenza Virus Infection in Mice , 1999, Journal of Virology.

[31]  S Oehen,et al.  Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. , 1998, Journal of immunology.

[32]  J. Ulmer,et al.  Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA , 1998, Journal of Virology.

[33]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[34]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[35]  R. Webster,et al.  A pandemic warning? , 1997, Nature.

[36]  J. Ulmer,et al.  Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. , 1997, Vaccine.

[37]  J. Ulmer,et al.  Priming of Cytotoxic T Lymphocytes by DNA Vaccines: Requirement for Professional Antigen Presenting Cells and Evidence for Antigen Transfer from Myocytes , 1997, Molecular medicine.

[38]  R. Webster,et al.  Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin , 1997, Journal of virology.

[39]  D. Ho,et al.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry , 1997, Journal of virology.

[40]  J. Yewdell,et al.  MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. , 1997, Journal of immunology.

[41]  E. D. Kilbourne,et al.  Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. , 1996, Virology.

[42]  J. Shiver,et al.  Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus , 1995, Nature Medicine.

[43]  J. Ulmer,et al.  Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. , 1994, Vaccine.

[44]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[45]  E. Prokudina,et al.  Localization of the influenza virus nucleoprotein: cell-associated and extracellular non-virion forms. , 1991, The Journal of general virology.

[46]  E. Paoletti,et al.  Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. , 1990, The Journal of general virology.

[47]  B. Moss,et al.  Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Oxford,et al.  Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells , 1977, Nature.

[49]  Robert Schechter,et al.  Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[50]  Eric C J Claas,et al.  Human influenza A H 5 N 1 virus related to a highly pathogenic avian influenza virus , 2005 .

[51]  R. Couch.  An overview of serum antibody responses to influenza virus antigens. , 2003, Developments in biologicals.

[52]  H. Davis.  Intramuscular and intradermal injection of DNA vaccines in mice and primates. , 2000, Methods in molecular medicine.

[53]  K. Subbarao,et al.  Influenza vaccines: present and future. , 1999, Advances in virus research.

[54]  H. Aihara,et al.  Gene transfer into muscle by electroporation in vivo. , 1998, Nature biotechnology.

[55]  R. Webster,et al.  DNA vaccines. , 1996, AIDS research and human retroviruses.

[56]  R. Webster,et al.  Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. , 1993, Vaccine.